ReviewFrontiers in oncology2026
The pro-metastatic effect and mechanism of immune cells in tumor metastasis.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor metastasis is the leading cause of cancer-related deaths, and its occurrence is not only determined by the invasive capacity of tumor cells themselves but is also profoundly influenced by the dynamic remodeling of the immune system. Recent studies over the past decade have shown that the immune mechanisms in tumor metastasis have expanded from the classical failure of immune surveillance to a systemic process involving immune cell functional remodeling, the construction of the pre-metastatic niche (PMN), and tumor immune editing. This review systematically reviews the tumor promoting mechanisms of various immune cells such as T cells, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), tumor-associated neutrophils (TANs), regulatory B cells (Bregs), tumor-associated natural killer cells (TANKs) and dendritic cells (DCs) in each stage of metastasis, and critically discusses the limitations, conceptual controversies, and future directions of current research. This review seeks to establish a systematic framework to enhance the understanding of immune cell mechanisms involved in tumor metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.